Atogepant is a selective oral small-molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor. It is a secondary carboxamide approved for use in migraine treatment.
콘텐츠 범위: 이 페이지의 정보는 화학물질 식별 및 산업 공급·연구개발·제조 맥락을 대상으로 합니다. 치료 효능 주장, 의료 조언 또는 의약품 사용 지침에 해당하지 않습니다.
이 화합물을 구매하거나 공급하시겠습니까?
재고를 등록하거나 구매 요청을 게시하세요
CAS 1374248-81-3
Ubrogepant
calcitonin gene-related peptide receptor antagonist
Rimegepant
calcitonin gene-related peptide receptor antagonist
Rimegepant sulfate
calcitonin gene-related peptide receptor antagonist
(S)-crizotinib
active pharmaceutical ingredient
Ribociclib succinate
Active pharmaceutical ingredient
Rociletinib
active pharmaceutical ingredient
Trilaciclib
active pharmaceutical ingredient
(3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
QIVUCLWGARAQIO-OLIXTKCUSA-N
C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F